Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Christoph Kreer; Matthias Zehner; Timm Weber; Meryem S Ercanoglu; Lutz Gieselmann; Cornelius Rohde; Sandro Halwe; Michael Korenkov; Philipp Schommers; Kanika Vanshylla; Veronica Di Cristanziano; Hanna Janicki; Reinhild Brinker; Artem Ashurov; Verena Krähling; Alexandra Kupke; Hadas Cohen-Dvashi; Manuel Koch; Jan Mathis Eckert; Simone Lederer; Nico Pfeifer; Timo Wolf; Maria J G T Vehreschild; Clemens Wendtner; Ron Diskin; Henning Gruell; Stephan Becker; Florian Klein

doi:10.1016/j.cell.2020.06.044

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Cell. 2020 Aug 20;182(4):843-854.e12. doi: 10.1016/j.cell.2020.06.044. Epub 2020 Jul 13.

Authors

Christoph Kreer¹, Matthias Zehner¹, Timm Weber¹, Meryem S Ercanoglu¹, Lutz Gieselmann¹, Cornelius Rohde², Sandro Halwe², Michael Korenkov¹, Philipp Schommers³, Kanika Vanshylla¹, Veronica Di Cristanziano⁴, Hanna Janicki¹, Reinhild Brinker⁵, Artem Ashurov¹, Verena Krähling², Alexandra Kupke², Hadas Cohen-Dvashi⁶, Manuel Koch⁷, Jan Mathis Eckert⁸, Simone Lederer⁹, Nico Pfeifer¹⁰, Timo Wolf¹¹, Maria J G T Vehreschild¹¹, Clemens Wendtner¹², Ron Diskin⁶, Henning Gruell¹³, Stephan Becker², Florian Klein¹⁴

Affiliations

¹ Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.
² Institute of Virology, Faculty of Medicine, Philipps University Marburg, 35043 Marburg, Germany; German Center for Infection Research, Partner Site Gießen-Marburg-Langen, 35043 Marburg, Germany.
³ Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
⁴ Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany.
⁵ Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany.
⁶ Department of Structural Biology, Weizmann Institute of Science, 76100 Rehovot, Israel.
⁷ Institute for Dental Research and Oral Musculoskeletal Biology and Center for Biochemistry, University of Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany.
⁸ Faculty of Medicine, University of Würzburg, 97080 Würzburg, Germany.
⁹ Institute for Translational Bioinformatics, University Hospital Tübingen and University of Tübingen, 72076 Tübingen, Germany.
¹⁰ Faculty of Medicine, University of Tübingen, 72076 Tübingen, Germany; Methods in Medical Informatics, Department of Computer Science, University of Tübingen, 72076 Tübingen, Germany; German Center for Infection Research, Partner Site Tübingen, 72076 Tübingen, Germany.
¹¹ Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany.
¹² Department of Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig Maximilians University, 80804 Munich, Germany.
¹³ Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany.
¹⁴ Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany. Electronic address: florian.klein@uk-koeln.de.

Abstract

The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 with IC₁₀₀ as low as 0.04 μg/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.

Keywords: 2019-nCoV; COVID-19; SARS-CoV-2; monoclonal antibody; neutralizing antibody; single B cell analysis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing / genetics
Antibodies, Neutralizing / immunology
Antibodies, Neutralizing / isolation & purification*
Antibodies, Viral / genetics
Antibodies, Viral / immunology
Antibodies, Viral / isolation & purification*
B-Lymphocytes / immunology
Betacoronavirus / immunology
COVID-19
Coronavirus Infections / immunology*
Humans
Immunoglobulin Variable Region / genetics
Immunoglobulin Variable Region / immunology
Immunologic Memory
Longitudinal Studies
Pandemics
Pneumonia, Viral / immunology*
SARS-CoV-2
Somatic Hypermutation, Immunoglobulin

Substances

Antibodies, Neutralizing
Antibodies, Viral
Immunoglobulin Variable Region